Fig 1: Effect of CRID3 on Th1, Th2, and Th17 cells in the injured spinal cord as distinguished by FCM. a Representative images of FCM in the spinal cords in sham, SCI (vehicle), and SCI (CRID3) groups. In the FSC/SSC pseudocolor plot, the same size “region” of lymphocytes was set for each sample, and then analyzed the proportion of each Th subsets in the “region” of CD3+CD4+ in CD3/CD4 pseudocolor plots. b Quantitative analysis of the indicated cells in the indicated groups. Data represent the mean ± SD (n = 6). **P < 0.01 (non-parametric Kruskal-Wallis ANOVA, followed by individual Mann-Whitney U tests)
Fig 2: Combination of RD@MBs with αPD-L1 chemoimmunotherapy activated systematic antitumor response. a Schematic illustration of the experiment design for antitumor immune responses. b The proportions of CTLs (CD3+CD4−CD8+) in spleens. c FCM results of CTLs (CD3+CD4−CD8+) in spleen. d FCM results of CTLs (CD3+CD4−CD8+) in tumor. e The proportions of Tregs (CD3+CD4+Foxp3+) in spleens. f-g The proportions of CTLs (CD3+CD4−CD8+) and Tregs (CD3+CD4+Foxp3+) in tumors. h IFN-γ levels in serum. Data are expressed as mean ± SD (n = 3). Statistical significances were calculated via Student’s t test, *p < 0.05, **p < 0.01 and ***p < 0.001
Supplier Page from Thermo Fisher Scientific for CD3 Antibody PE